The study is a Phase 1, single-centre, open label, micro-dosing study. The aim is to investigate an innovative new tracer, [18F]CETO, as a potential alternative to adrenal vein sampling for the lateralisation of primary aldosteronism (PA).
Study Name: A Phase 1 Clinical Trial Evaluating the Safety and Efficacy of up to Two Administrations of the Adrenal PET Tracer [18F]CETO in Healthy Volunteers and Patients With Primary Aldosteronism
Conditions: Primary aldosteronism
Interventions: Combination Product: [18F]CETO
Locations: Addenbrooke Hospital, United Kingdom
Study link: https://clinicaltrials.gov/ct2/show/NCT04529018
To search for other studies by topic, location, or status, go to our Clinical Studies page.